Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

Dec 4 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab blockbuster drug Imfinzi to treat some adults with limited-stage small cell lung cancer, the ...

On the heels of two FDA approvals in lung cancer treatments, what innovations are next? As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung ...

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...